Last 18.50 GBp
Change Today -1.50 / -7.50%
Volume 61.1K
SPHR On Other Exchanges
As of 11:35 AM 03/5/15 All times are local (Market data is delayed by at least 15 minutes).

sphere medical holding plc (SPHR) Snapshot

20.00 GBp
Previous Close
20.00 GBp
Day High
20.00 GBp
Day Low
18.25 GBp
52 Week High
06/10/14 - 30.00 GBp
52 Week Low
03/5/15 - 18.25 GBp
Market Cap
Average Volume 10 Days
-0.08 GBp
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

sphere medical holding plc (SPHR) Related Businessweek News

No Related Businessweek News Found

sphere medical holding plc (SPHR) Details

Sphere Medical Holding plc, together with its subsidiary, Sphere Medical Limited, researches, develops, and manufactures a range of monitoring and diagnostic products in the United Kingdom and internationally. Its products deliver real time analysis of blood gases, electrolytes, and drug levels at the patient’s bedside. The company’s products comprise Proxima system, a disposable multi-parameter microanalyser, for use in the intensive care unit and operating room; Pelorus, a propofol measurement system that measures the concentration of the intravenous anesthetic propofol in blood samples; and cardiopulmonary bypass monitor, which is used to frequently measure the blood chemistry during cardiopulmonary bypass surgery. It has a collaboration agreement with Ortho-Clinical Diagnostics, Inc. for the development of Proxima. The company was formerly known as Sphere Medical Holding Limited and changed its name to Sphere Medical Holding plc in November 2006. The company was incorporated in 2001 and is headquartered in Cambridge, the United Kingdom.

67 Employees
Last Reported Date: 03/4/14
Founded in 2001

sphere medical holding plc (SPHR) Top Compensated Officers

Chief Financial Officer, Company Secretary an...
Total Annual Compensation: 150.0K GBP
Compensation as of Fiscal Year 2013.

sphere medical holding plc (SPHR) Key Developments

Sphere Medical Holding plc Announces Appointment of Directors

Sphere Medical Holding plc announced the appointment of Dr. David Martyr and Meinhard Schmidt to the company's Board as Non-Executive Directors with immediate effect. Dr. Martyr has held several senior level positions of medical, diagnostic, life science and laser technology companies for more than 20 years.  He has extensive experience in driving growth, profitability and innovation in medical technology businesses. David is currently CEO of Tecan AG. David is also a Non-Executive Director of ALDA (Analytical Life Science Diagnostics Association), based near Washington DC. Mr. Schmidt joins Sphere Medical with more than 20 years of international experience as an entrepreneur and senior executive in the healthcare, diagnostics and medical devices industries. Between 1998 and 2008 Meinhard was at Roche Diagnostics where he held various senior leadership roles in Diabetes Care, Lab Diagnostics and was Senior VP and Head of Roche Decentralized Solutions. Meinhard is currently a Board Director at Quanta FS Ltd, valuationLAB AG and Chairman at Promimic AB.

Sphere Medical Holding plc Appoints Michael Quintel to its Medical Advisory Board

Sphere Medical Holding plc announced the appointment of Professor Michael Quintel to its Medical Advisory Board. Professor Quintel is a clinician within the German and European intensive care profession.  He is the Director of the Department of Anaesthesiology, Emergency and Intensive Care Medicine at the University of Göttingen, Germany. Professor Quintel will work alongside Professor Jean-Louis Vincent, Professor of Intensive Care at the Université Libre de Bruxelles and the Head of the Department of Intensive Care, Erasme University Hospital (University of Brussels) and Dr. Tom Clutton-Brock, Head of Anaesthesia & Intensive Care at The University of Birmingham Medical School and Associate Medical Director at the University Hospital Birmingham NHS Foundation Trust.

Sphere Medical Holding Announces Positive Outcome for Proxima in Post Market Clinical Follow-Up Study

Sphere Medical Holding PLC announced a successful Proxima 3 Post Market Clinical Follow-up Study at the Queen Elizabeth Hospital, Birmingham, UK. The study, which was completed on schedule, met the primary end point to demonstrate excellent agreement with the standard bench top blood gas analysers at the Queen Elizabeth Hospital measuring various arterial blood parameters in a clinical setting. A total of twenty intensive care unit patients with a range of clinical conditions, including trauma, head injury, post-surgical recovery and sepsis, were included in the study. Patients were connected to the Proxima system for up to three days during which as many as thirty three blood gas measurements were obtained per Proxima device. Use of the Proxima system was carried out by the clinical staff at the Queen Elizabeth Hospital who each underwent an initial ninety minute training programme.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SPHR:LN 18.50 GBp -1.50

SPHR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for SPHR.
View Industry Companies

Industry Analysis


Industry Average

Valuation SPHR Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 622.0x
Price/Book 1.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales 619.9x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SPHERE MEDICAL HOLDING PLC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at